“`html
Innovent Biologics (HKEX: 01801), a biopharmaceutical firm focused on developing and commercializing therapies for a range of conditions including oncology, autoimmune disorders, and cardiovascular diseases, announced it will present multiple research findings at the 34th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20. The company will showcase post-hoc analyses from Phase 2 and Phase 3 trials of IBI112 (picankibart), an IL-23p19 monoclonal antibody, along with preclinical results for IBI3013, targeting IL-15, and IAR129, a bispecific antibody targeting IL-4R/OX40L. These presentations will be made via ePoster.
Specific studies selected for presentation include:
Title: Development and Characterization of IBI3013, a Novel Half-life Extended Monoclonal Antibody Targeting Interleukin-15 (IL-15)
Abstract #: 1882
Presentation Form: ePoster
Time: 2025 September 17, 07:00 AM (CEST)
Title: Development and characterization of IAR129, a novel bispecific antibody co-blocking IL-4Ra and OX40L for atopic dermatitis
Abstract #: 2648
Presentation Form: ePoster
Time: 2025 September 17, 07:00 AM (CEST)
Title: Efficacy and safety of picankibart in patients with psoriasis who had been treated with biologics: a multicenter, open-label Phase 2 trial
Abstract #: 1706
Presentation Form: ePoster
Time: 2025 September 17, 07:00 AM (CEST)
Title: Efficacy of picankibart in moderate-to-severe plaque psoriasis patients with scalp psoriasis: a post-hoc analysis of a Phase 3, randomized, double-blind trial
Abstract #: 4799
Presentation Form: ePoster
Time: 2025 September 17, 07:00 AM (CEST)
Title: Efficacy of picankibart in genital psoriasis: results from the Phase 3 randomized, double-blind CLEAR-1 study
Abstract #: 6421
Presentation Form: ePoster
Time: 2025 September 17, 07:00 AM (CEST)
Title: Efficacy of a new IL-23p19 inhibitor picankibart in the treatment of nail psoriasis: a post-hoc analysis of phase 3 CLEAR-1 study
Abstract #: 7526
Presentation Form: ePoster
Time: 2025 September 17, 07:00 AM (CEST)
Title: Efficacy of Picankibart in Moderate-to-Severe Plaque Psoriasis Between Biologic-Experienced and Biologic-Naive Patients: A 52-Week results from the Phase 3 CLEAR-1 Study
Abstract #: 7541
Presentation Form: ePoster
Time: 2025 September 17, 07:00 AM (CEST)
Innovent’s strategy revolves around targeting key disease pathways with a focus on innovative monoclonal and bispecific antibodies. “We are actively investigating crucial disease driver pathways and their interactions, leveraging our diverse technology platforms to address unmet needs across various dermatological conditions,” stated a company spokesperson. The company aims to offer patients improved efficacy, less frequent dosing schedules, and enhanced symptom control even after treatment cessation.
The potential approval of picankibart, expected by the end of the year, marks a significant milestone for Innovent. The company’s Chief R&D Officer emphasized the drug’s potential as a “best-in-class IL-23p19 inhibitor,” highlighting its rapid action, potent and lasting effectiveness, and convenient quarterly dosing schedule. This, he asserts, could significantly benefit the substantial number of psoriasis patients seeking new treatment options. Furthermore, Innovent is committed to furthering its commitment to global innovation and accelerating clinical development of promising molecules, seeking to deliver transformative therapies that improve the lives of patients worldwide.
Innovent Biologics has established itself as a prominent biopharmaceutical company since its founding in 2011. The company has a diverse portfolio including 16 marketed products with 2 new drug applications currently under regulatory review. The company’s approach involves strategic partnerships with over 30 global healthcare companies, including Eli Lilly and Sanofi, highlighting its position in the competitive biopharmaceutical landscape. The company’s strong pipeline and collaborative approach underscore its mission to deliver affordable, high-quality biopharmaceuticals to patients globally. The EADV Congress presentations provide valuable insights into Innovent’s ongoing research and development efforts in the field of immunology and dermatology.
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics (“Innovent”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/9390.html
